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cocci are more common. 3) Embolisms in other locations are more frequent. 4) Septic
shock is more frequent. 5) Death and the need for valve surgery are not influenced by the
existence of these embolisms. 
1143-140 Reoperative Valve Replacement With the St. Jude 
Medical Valve Prosthesis: Long-Term Follow-Up
Robert W. Emery, Kit V. Arom, Christopher Krogh, Lyle D. Joyce, Demetre Nicoloff, 
Minnesota Cardiovascular & Thoracic Surgeons, LLC, St. Paul, MN
OBJECTIVE: From 6/78 – 9/02, 451 redo open heart patients (following various primary
cardiac operations) age range 18-91 years (average age 62 ± 14) underwent single-valve
replacement with the St. Jude Medical (SJM) heart valve. Of 248 patients having aortic
(AVR) and 203 patients having mitral valve replacements (MVR), 35% and 21% had con-
comitant coronary bypass respectively.
METHODS: Cardiac Surgical Associates has maintained an independent database of
our patients with the SJM prosthesis since the world’s first implant in 10/77. Patients were
contacted by questionnaire and/or phone from 11/02 through 6/03. Hospital course and
valve-related events were verified by patient chart review and/or physician contact.
RESULTS: Follow-up was 95% complete for a total of 3,115 patient years (1,671 AVR;
1,443 MVR). Follow-up ranged from 0.1 to 24.3 years (average 7 ± 6 years). Operative
mortality was 9% (10% AVR, 8% MVR). Five deaths (13%) were valve related. Freedom
from all late mortality at 24 years was 64% (70% AVR, 56% MVR), and from valve-related
mortality 83% (84% AVR, 82% MVR). Freedom from thromboembolic events was 85%
(91% AVR, 82% MVR), from bleeding events 83% (83%AVR, 82% MVR), from
endocarditis 97% (97% AVR, 97% MVR), from valve thrombosis 98% (99% AVR, 98%
MVR), and from subsequent reoperation 94% (95% AVR, 94% MVR),. There were no
structural failures.
CONCLUSION: Reoperative valve replacement carries a significant operative mortality,
but long term results with the SJM valve show a low event rate, a durable prosthetic valve
and excellent long-term patient survival.
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851-1 Ischemic Mitral Regurgitation Does Not Influence 
Postinfarction Ventricular Remodeling
Sina L. Moainie, Yoshiharu Enomoto, Joseph H. Gorman, III, Benjamin M. Jackson, 
Theodore Plappert, Martin G. St. John-Sutton, Ahmad Zeeshan, Robert C. Gorman, 
University of Pennsylvania, Philadelphia, PA
Background: Despite sparse clinical data, surgical treatment for ischemic mitral regurgi-
tation (IMR) has become more aggressive. We used four well-developed ovine models of
postinfarction left ventricular (LV) remodeling to test the hypothesis that IMR does not sig-
nificantly contribute to postinfarction LV remodeling.
Methods: Infarction of 21% to 24% of the LV was induced by coronary ligation in 71
sheep. Infarctions varied only by anatomic location: anteroapical (AA), n=26; anterobasal
(AB), n=16; laterobasal (LB), n=9 and posterobasal (PB) n= 20. End systolic volume
(ESV), end diastolic volume, end systolic muscle to cavity area ratio (ESMCAR), ejection
fraction (EF) and degree of IMR as determined by quantitative echocardiography were
assessed before infarction and at 2, 5 and 8 weeks after infarction to evaluate the extent
of LV remodeling.
Results: All infarcts resulted in significant postinfarction remodeling and decreased EF
(table). AA infarcts led to LV aneurysms and resulted in more severe remodeling than the
three other infarct locations. Only PB infarcts caused severe and progressive IMR.
Remodeling due to PB infarcts was not more severe than that caused by infarcts at other
locations.
Conclusion: The extent of postinfarction remodeling is determined by infarct size and
location. The development of IMR does not contribute to adverse remodeling. IMR is a
manifestation rather than a cause of postinfarction remodeling. The current aggressive
surgical approach to IMR should be reassessed. 
2:15 p.m.
851-2 Reduction in Functional Mitral Regurgitation Using the 
Coapsys Annuloplasty Device in Patients Undergoing 
Off-Pump Coronary Artery Bypass Grafting: A 
Quantitative Echo Analysis
Sanjay Mittal, Yugal Mishra, Yatin Mehta, Naresh Trehan, Escorts Heart Institute and 
Research Centre, New Delhi, India
Background: We are evaluating a novel implantable device (Myocor® Coapsys™ Annu-
loplasty System) intended to treat functional mitral regurgitation (MR) on a beating heart
as conventional surgical correction increases mortality and morbidity over CABG alone.
Changes in mitral valve (MV) geometry induced by the device were evaluated using echo
techniques.
Methods: The Coapsys device was surgically implanted in 20 patients (mean age 58.7 ±
8.1 years, 3 females, mean ejection fraction 37.3 ± 6.2 %) with sustained MR grade 2 or
more after undergoing concomitant CABG. Patients with structural abnormalities of the
MV or its apparatus were excluded . Coapsys consists of anterior and posterior epicardial
pads connected by a flexible sub-valvular chord. The device is tightened under echo
guidance to minimize MR. Echo parameters (MR Grade; Maximum MR jet area; end-
diastolic antero-posterior (A-P) annular dimension and MV tenting area) were studied
pre-operatively and post-operatively (prior to discharge and 3 months).
Results: Implants were performed off-pump without device related adverse events. Echo
parameters were as Table 1. [* p<0.005 compared to pre-implantation]
Table 1 
Conclusions: The Coapsys device can be safely implanted on the beating heart.
Implantation of the device results in significant reductions in MR. MR jet area, A-P dimen-
sion, and MV tenting area are also significantly reduced. These functional and geometric
changes are maintained at 3-months.
2:30 p.m.
851-3 Staged Initial Percutaneous Coronary Intervention 
Followed by Valve Surgery (“Hybrid” Approach) for 
Patients With Complex Coronary and Valve Disease
John G. Byrne, Marzia Leacche, Tomislav Mihaljevic, Sary F. Aranki, James D. Rawn, 
Lawrence H. Cohn, Brigham and Women's Hospital, Boston, MA
Background:With advancements in percutaneous coronary interventions (PCI), some
patients requiring coronary revascularization and valve surgery may be better served
with a “hybrid” approach involving initial planned PCI followed by valve surgery in a
staged fashion rather than conventional high-risk valve/CABG. This may be particularly
relevant in hemodynamically unstable patients after acute coronary syndromes, and
some patients requiring valve reoperations.
Methods: We retrospectively analyzed 26 consecutive patients with coronary artery and
valve disease who were treated with planned initial PCI followed by valve surgery during
the same hospitalization between September 1997 and August 2003.
Results: Median age was 72.5 years (range 53-91 years), with 12M/14F. Mean NYHA
was 3.5±0.6. Acute myocardial infarction was present in 10/26 (38%) with cardiogenic
shock in 4/26 (15%) and low cardiac output syndrome in 6/26 (23%). 7/26 (27%) required
preoperative intubation. Balloon angioplasty was performed in every patient (n=26), fol-
Group I
Hepatosplenic or Renal 
Embolisms
n= 33
(%)
Group II
n= 305
(%)
P value
Prosthetic endocarditis 30.3 36.7 0.46
Embolisms in other locations 48.5 13.4 <0.001
Stroke at admission 33.3 15.1 0.008
Splenomegaly 24.2 10.9 0.04
S. aureus 30.3 16.1 0.04
Enterococci 18.2 8.2 0.05
Vegetations detected by TEE 97.0 78.0 0.01
Vegetation Size _10 mm 90.0 70.8 0.02
Septic shock 27.3 9.5 0.002
Persistent infection 54.5 32.8 0.01
Surgery 54.5 53.1 0.87
Mortality 39.4 30.8 0.31
Infarct Location IMR at 8 weeks
(0=no MR, 
4=severe MR)
ESV at 8 
weeks as % of 
preinfarction
ESMCAR at 
8weeks as % of 
preinfarction
EF at 8 weeks 
as % of 
preinfarction
Anteroapical(AA) 
n=26
0.7± 0.2 238±11* 86± 4 76± 34
Anterobasal(AB) 
n=16
0.5± 0.2 203±17 75±6 75± 38
Laterobasal(LB)
n=9
0.2± 0.2 191±19 83± 8 74± 23
Posterobasal(PB) 
n=20
2.8± 0.2** 218±12 74± 7 73± 21
* ESV significantly greater for AA infarcts than all other infarct locations at 8 wks
** IMR significantly greater for PB infarcts than all other infarct locations at 8 wks
Pre-implant Discharge Three Month
MR Grade 3.0±0.6 1.1±1.0* 1.3±0.8*
MR jet area (cm²) 7.9±3.7 3.5±2.0* 3.6±1.6*
Annular A-P Dimension 2.8±0.4 2.4±0.4* 2.6±0.4*
Mitral Tenting Area 3.9±1.0 2.8±1.0* 2.9±0.9*
